RN-1734|cas:946387-07-1|西域试剂

RN-1734,99.86%

产品编号：Bellancom-19975| CAS NO：946387-07-1| 分子式：C₁₄H₂₂Cl₂N₂O₂S| 分子量：353.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19975	￥550.00	杭州北京（现货）
Bellancom-19975	￥770.00	杭州北京（现货）
Bellancom-19975	￥3500.00	杭州北京（现货）
Bellancom-19975	￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

RN-1734

产品介绍

RN-1734 是一种选择性 TRPV4 通道拮抗剂，完全拮抗 4αPDD 介导的 TRPV4 活化，作用于 hTRPV4, mTRPV4, 和 rTRPV4，IC₅₀ 分别为 2.3 μM、5.9 μM、3.2 μM。RN-1734 能明显降低肿瘤坏死因子 α (TNF-α) 和白细胞介素 1β (IL-1β) 的产生，而不改变 olig2- 阳性细胞的数量。

生物活性

RN-1734 is selective antagonist of the TRPV4 channel, completely antagonizes 4αPDD-mediated activation of TRPV4 with comparable, low micromolar IC₅₀s for all three species (hTRPV4: 2.3 μM, mTRPV4: 5.9 μM, rTRPV4: 3.2 μM). RN-1734 clearly decreases the production of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) without altering the number of olig2-positive cells.

体外研究

RN-1734 (27 hours; 10μM) reverses the increase in the apoptotic rate of oligodendrocytes induced by CM (LPS-activated microglia group) apoptosis.
RN-1734 (27 hours; 10μM) alleviates CM-induced decreases in CNP.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	Microglial cells
Concentration:	27 hours
Incubation Time:	10μM
Result:	Significantly decreased the percentage of cleaved-caspase 3 positive cells.

Western Blot Analysis

Cell Line:	Microglial cells
Concentration:	27 hours
Incubation Time:	10 μM
Result:	Alleviated CM (with LPS only)-induced decreases in CNP.

体内研究
(In Vivo)

RN-1734 (0.5 μl; microinjector pump; daily for 5 weeks) significantly reverses the decrease in CNP protein and improves myelination in CPZ-induced demyelination mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CPZ-induced demyelination mouse model (C57BL/6 male mice)
Dosage:	0.5 μl (10 μM in 5% DMSO and 0.9% NaCl)
Administration:	Microinjector pump for 5 weeks
Result:	Significantly reversed the decrease in CNP protein and improved myelination in CPZ-induced demyelination mouse.

体内研究

RN-1734 (0.5 μl; microinjector pump; daily for 5 weeks) significantly reverses the decrease in CNP protein and improves myelination in CPZ-induced demyelination mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CPZ-induced demyelination mouse model (C57BL/6 male mice)
Dosage:	0.5 μl (10 μM in 5% DMSO and 0.9% NaCl)
Administration:	Microinjector pump for 5 weeks
Result:	Significantly reversed the decrease in CNP protein and improved myelination in CPZ-induced demyelination mouse.

体内研究

RN-1734 (0.5 μl; microinjector pump; daily for 5 weeks) significantly reverses the decrease in CNP protein and improves myelination in CPZ-induced demyelination mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CPZ-induced demyelination mouse model (C57BL/6 male mice)
Dosage:	0.5 μl (10 μM in 5% DMSO and 0.9% NaCl)
Administration:	Microinjector pump for 5 weeks
Result:	Significantly reversed the decrease in CNP protein and improved myelination in CPZ-induced demyelination mouse.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (70.76 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8304 mL	14.1519 mL	28.3038 mL
5 mM	0.5661 mL	2.8304 mL	5.6608 mL
10 mM	0.2830 mL	1.4152 mL	2.8304 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 3.25 mg/mL (9.20 mM); Clear solution

此方案可获得 ≥ 3.25 mg/mL (9.20 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 32.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 3.25 mg/mL (9.20 mM); Clear solution

此方案可获得 ≥ 3.25 mg/mL (9.20 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 32.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 3.25 mg/mL (9.20 mM); Clear solution

此方案可获得 ≥ 3.25 mg/mL (9.20 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 32.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。